HealthEquity, Inc. (NASDAQ:HQY) Director Sells $2,418,000.00 in Stock

HealthEquity, Inc. (NASDAQ:HQY) Director Stuart B. Parker sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $96.72, for a total transaction of $2,418,000.00. Following the completion of the sale, the director now directly owns 19,061 shares in the company, valued at approximately $1,843,579.92. This trade represents a 56.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

HealthEquity Stock Performance

HQY traded up $0.62 during trading on Friday, hitting $95.62. 631,708 shares of the stock were exchanged, compared to its average volume of 634,230. The company has a quick ratio of 4.10, a current ratio of 3.20 and a debt-to-equity ratio of 0.51. HealthEquity, Inc. has a 1-year low of $62.10 and a 1-year high of $105.82. The stock has a fifty day moving average price of $93.81 and a two-hundred day moving average price of $84.07. The firm has a market capitalization of $8.29 billion, a P/E ratio of 87.88, a PEG ratio of 1.10 and a beta of 0.55.

Analysts Set New Price Targets

A number of equities research analysts have commented on HQY shares. Barrington Research increased their price objective on shares of HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research report on Monday, December 2nd. Deutsche Bank Aktiengesellschaft increased their target price on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Mizuho began coverage on HealthEquity in a research note on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price target on the stock. The Goldman Sachs Group initiated coverage on HealthEquity in a research report on Friday, November 15th. They set a “neutral” rating and a $108.00 price objective for the company. Finally, BTIG Research raised their target price on HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $110.71.

Hedge Funds Weigh In On HealthEquity

A number of hedge funds have recently modified their holdings of HQY. International Assets Investment Management LLC purchased a new stake in HealthEquity in the 2nd quarter valued at $35,000. Paladin Wealth LLC acquired a new position in HealthEquity in the third quarter valued at $39,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of HealthEquity in the second quarter valued at about $73,000. GAMMA Investing LLC boosted its stake in shares of HealthEquity by 57.8% during the third quarter. GAMMA Investing LLC now owns 939 shares of the company’s stock worth $77,000 after buying an additional 344 shares during the period. Finally, Quarry LP grew its holdings in shares of HealthEquity by 418.8% during the third quarter. Quarry LP now owns 1,349 shares of the company’s stock worth $110,000 after buying an additional 1,089 shares during the last quarter. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.